I strongly disagree. The second quarter guidance for the year was 5.5-7 million, looks more like 8-9 million, and the revenue seems to be recurring. Just not another record quarter. IMO it's a hold if you have a position and a buy if you don't.
sdman...actually i apologize. You are not one of the bashers. Anyhow i don't think they "postponed" anything and if they did for sure not because of Q release. It was not that disappointing in my opinion. There core sales increased. This stock is hold stock for loooong term. In 6 years from now the importance of stem cell comp[anies will increase. The revenue will increase big time
The earnings for Q3 were 7% lower than for Q2. That's disappointing, but it is still on track for $8 to $10 million for 2013. By the way, I am one of the "idiots" who is holding lots of BLFS at $ .10 a share.